{"organizations": [], "uuid": "4b93075c49f34adbec0197c52bf3f4d592fc5ed9", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/esperion-thera-study/esperions-cholesterol-drug-succeeds-in-mid-stage-study-idUSL3N1R94GB", "country": "US", "domain_rank": 408, "title": "Esperion's cholesterol drug succeeds in mid-stage study", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-27T14:51:00.000+03:00", "replies_count": 0, "uuid": "4b93075c49f34adbec0197c52bf3f4d592fc5ed9"}, "author": "", "url": "https://www.reuters.com/article/esperion-thera-study/esperions-cholesterol-drug-succeeds-in-mid-stage-study-idUSL3N1R94GB", "ord_in_thread": 0, "title": "Esperion's cholesterol drug succeeds in mid-stage study", "locations": [], "entities": {"persons": [{"name": "akankshita mukhopadhyay", "sentiment": "none"}], "locations": [{"name": "bengaluru", "sentiment": "none"}], "organizations": [{"name": "esperion", "sentiment": "negative"}, {"name": "esperion therapeutics inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 27, 2018 / 11:53 AM / Updated 10 minutes ago Esperion's cholesterol drug succeeds in mid-stage study Reuters Staff 1 Min Read March 27 (Reuters) - Esperion Therapeutics Inc said on Tuesday a mid-stage study of its experimental oral drug met the main goal of reducing cholesterol. Esperionâ€™s 8-week study tested a 180 mg per day dose of its drug, bempedoic acid, versus a placebo in 58 patients with high cholesterol. Shares of the company were up 2.17 percent at $73.35 in premarket trading. (Reporting by Akankshita Mukhopadhyay in Bengaluru)", "external_links": [], "published": "2018-03-27T14:51:00.000+03:00", "crawled": "2018-03-27T15:13:47.020+03:00", "highlightTitle": ""}